Limiris®

Limiris® is a genetically engineered biological agent that inhibits interleukin-1β.

The active ingredient of Limiris® is kanakinumab, a human monoclonal antibody of the IgG1/kappa isotype to interleukin–1b, obtained in the CHO cell line using recombinant DNA technology.

Canakinumab inhibits the action of interleukin-1β, whose levels are elevated in autoinflammatory diseases and gouty arthritis.

Canakinumab is used in adults, adolescents, and children aged 2 years and older for the treatment of autoinflammatory periodic fever syndromes, Still's disease, and systemic juvenile idiopathic arthritis, as well as in adults for the treatment of gouty arthritis.

GENERIUM is the first company in Russia to develop and manufacture a biosimilar of canakinumab.